Report on Riociguat (Adempas®): A Comprehensive Monograph

Executive Summary & Overview

Riociguat, marketed under the brand name Adempas®, is a first-in-class, orally administered stimulator of the enzyme soluble guanylate cyclase (sGC).[1] It represents a novel therapeutic pathway for the management of two severe and life-threatening forms of pulmonary hypertension (PH). The primary approved indications for Riociguat are the treatment of adults with specific subsets of chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) and pulmonary arterial hypertension (PAH, WHO Group 1).[3]

The mechanism of action of Riociguat is unique among pulmonary vasodilators. It targets the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway, which is known to be impaired in patients with PH.[5] Riociguat exerts its therapeutic effect through a dual mode of action: it directly stimulates sGC independent of NO and it also sensitizes sGC to the effects of endogenous NO. This dual action restores the signaling pathway, leading to increased cGMP synthesis, which in turn results in significant vasodilation, as well as potential anti-proliferative and anti-fibrotic effects in the pulmonary vasculature.[5]

Clinically, Riociguat has demonstrated the ability to significantly improve exercise capacity, as measured by the 6-minute walk distance (6MWD), improve World Health Organization (WHO) Functional Class, and favorably modulate key hemodynamic parameters such as pulmonary vascular resistance (PVR).[2] It is particularly notable for being the first pharmacotherapy approved for patients with inoperable or persistent/recurrent CTEPH, addressing a significant unmet medical need.[2]

Despite its efficacy, the use of Riociguat is governed by a stringent and complex safety profile. The drug carries a Boxed Warning for Embryo-Fetal Toxicity due to a high risk of causing severe birth defects.[5] To manage this risk, Riociguat is available only through a mandatory and restricted Risk Evaluation and Mitigation Strategy (REMS) program, which imposes strict requirements on prescribers, pharmacies, and all female patients.[10] Furthermore, Riociguat is absolutely contraindicated for concurrent use with nitrates and phosphodiesterase-5 (PDE-5) inhibitors due to the profound risk of life-threatening hypotension.[10]

The complexity of Riociguat's management is a central feature of its clinical identity, as important as its novel mechanism. Its utility is inextricably linked to the capacity of the healthcare system and the patient to adhere to a rigorous safety protocol. Therefore, Riociguat is positioned as a significant but highly specialized therapeutic option, requiring expert physician oversight for its safe and effective administration in appropriately selected patients.

Identification and Physicochemical Properties

Riociguat is a small molecule drug that represents the first agent in the therapeutic class of soluble guanylate cyclase stimulators.[2] Its comprehensive identification is critical for research, regulatory, and clinical cross-referencing.

Nomenclature and Chemical Identity

• Generic Name: Riociguat [1]
• Brand Name: Adempas® [1]
• Manufacturer: Bayer HealthCare Pharmaceuticals Inc. [1]
• Development Code: BAY 63-2521 [1]
• Chemical Class: Riociguat is classified as a pyrazolopyridine, an aminopyrimidine, an organofluorine compound, and a carbamate ester.[1]
• Chemical Name: The formal IUPAC (International Union of Pure and Applied Chemistry) name is methyl N-[4,6-diamino-2-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate.[1] Minor syntactical variations of this name appear in different chemical databases and regulatory documents.[5]

Structural and Molecular Data

• Chemical Formula: C20​H19​FN8​O2​ [1]
• Molecular Weight: The average molecular mass is approximately 422.42 g/mol.[5] More precise values include 422.4157 g/mol (average) and 422.1615 g/mol (monoisotopic).[6]
• Chemical Structure: !(https://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/204819s006lbl.pdf\#page\=27 "Chemical structure of Riociguat") Structure as depicted in FDA labeling documents.4

Physicochemical Properties

• Physical Description: Riociguat is a white to yellowish, crystalline, non-hygroscopic substance.[5]
• Stability: In its solid form, it is stable to temperature, light, and humidity.[5]
• Solubility: Riociguat exhibits pH-dependent solubility. It has reduced solubility at neutral pH compared to acidic medium, a property that underlies its interaction with agents that increase gastric pH, such as antacids.[20] It is soluble in organic solvents like dimethylformamide (DMF) and dimethyl sulfoxide (DMSO) at 10 mg/mL.[16]

Drug and Chemical Identifiers

The numerous identifiers assigned to Riociguat are essential for its unambiguous identification across various scientific and regulatory databases. Consolidating these codes provides a definitive reference point for researchers, clinicians, and other healthcare professionals, preventing ambiguity and facilitating further independent investigation.

Identifier Type	Value	Source(s)
DrugBank ID	DB08931	1
CAS Number	625115-55-1	1
UNII	RU3FE2Y4XI	1
ATC Code	C02KX05	1
PubChem CID	11304743	1
ChEMBL ID	CHEMBL2107834	1
KEGG ID	D09572	1
InChI	InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)	1
InChIKey	WXXSNCNJFUAIDG-UHFFFAOYSA-N	1
SMILES	CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC	1

Regulatory History and Market Status

The regulatory journey of Riociguat reflects its status as a significant therapeutic advancement for patient populations with a high unmet medical need. Its rapid and widespread approval across major global markets underscores the perceived strength of its clinical data and its breakthrough nature.

Development and Global Approvals

Riociguat was developed by Bayer HealthCare Pharmaceuticals, which remains the primary sponsor and market authorization holder.[1]

• First Global Approval: Riociguat received its first-ever global approval in Canada for the treatment of CTEPH.[9]
• U.S. Food and Drug Administration (FDA): The FDA approved Adempas on October 8, 2013.[2] This approval was notably swift, following a Priority Review designation granted in April 2013 and a unanimous recommendation for approval from the FDA's Cardiovascular and Renal Drugs Advisory Committee in August 2013.[13] A Priority Review designation is reserved for drugs that, if approved, would offer a significant improvement in the safety or effectiveness of treating a serious condition. The unanimous advisory committee vote further signaled a strong consensus on the drug's favorable benefit-risk profile, particularly given the lack of other approved medical therapies for inoperable CTEPH at the time.
• European Medicines Agency (EMA): Marketing authorization in the European Union was granted on March 27, 2014.[22]
• Japan Pharmaceuticals and Medical Devices Agency (PMDA): Approval in Japan was granted in January 2014.[1]

This condensed timeline of approvals across North America, Europe, and Asia highlights a global regulatory consensus on the drug's importance.

Orphan Drug Designation

Reflecting the rarity of the conditions it treats, Riociguat was granted orphan drug status by major regulatory bodies. This designation provides incentives for the development of drugs for rare diseases.

• EMA Designation: Designated as an orphan medicinal product in the EU on December 20, 2007, for the treatment of both PAH and CTEPH.[8]
• FDA Designation: Designated as an orphan drug in the U.S. on September 19, 2013, for the treatment of CTEPH.[21] The associated seven-year market exclusivity period for this indication expired on October 8, 2020.[21]

Patent Landscape and Generic Availability

The intellectual property protection for Riociguat illustrates a common pharmaceutical life-cycle management strategy. An initial, broad patent covering the class of compounds is followed by later, more specific patents on formulations or crystalline structures to extend market exclusivity.

• Key Patents: The foundational patent covering the general class of carbamate-substituted pyrazolopyridines (U.S. Patent 7,173,037) was set to expire in December 2026.[27] A later patent (U.S. Patent 10,662,188), covering specific crystalline forms (polymorphs) of Riociguat, extends protection for the approved indications until February 18, 2034.[27] This strategy effectively lengthens the drug's branded life, delaying the entry of lower-cost generics.
• Generic Entry: Despite the long-dated patents, a generic version of Riociguat, manufactured by MSN Laboratories, received FDA approval on September 1, 2022.[23] The availability of a generic version suggests that patent challenges or licensing agreements may have occurred, potentially increasing access to the therapy.

Commercial Information

The cost of Riociguat is substantial, reflecting its status as a specialized therapy for a rare disease. At the time of its initial approval, the estimated cost for a 30-day supply of Adempas was approximately USD $7,500.[1] This high cost can be a significant barrier to access for patients and a major consideration for healthcare payers.

Clinical Pharmacology

The clinical pharmacology of Riociguat is defined by its novel mechanism of action targeting the sGC enzyme and a complex pharmacokinetic profile that necessitates careful dose titration and awareness of numerous potential drug interactions.

4.1. Mechanism of Action (Pharmacodynamics)

Riociguat is a direct stimulator of soluble guanylate cyclase (sGC), an enzyme that functions as the primary receptor for endogenous nitric oxide (NO).[5] The therapeutic activity of Riociguat is rooted in its ability to enhance signaling through the NO-sGC-cGMP pathway, which is fundamentally impaired in pulmonary hypertension.

• The NO-sGC-cGMP Pathway: Under normal physiological conditions, NO is produced by endothelial cells and diffuses into adjacent vascular smooth muscle cells. There, it binds to the heme group of sGC, activating the enzyme.[2] Activated sGC catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). As a key intracellular second messenger, cGMP mediates a cascade of downstream effects, most notably the relaxation of vascular smooth muscle cells (vasodilation), as well as inhibition of cellular proliferation and fibrosis.[2]
• Pathophysiology in Pulmonary Hypertension: A hallmark of PH is endothelial dysfunction, which leads to impaired synthesis and bioavailability of NO. This deficiency results in insufficient stimulation of the NO-sGC-cGMP pathway, contributing to the characteristic vasoconstriction, vascular remodeling, and increased pulmonary vascular resistance of the disease.[2]
• Riociguat's Dual Mode of Action: Riociguat is distinguished by its unique, dual mechanism for enhancing this deficient pathway:

1. NO-Dependent Sensitization: Riociguat sensitizes sGC to the low levels of endogenous NO that may still be present. It achieves this by stabilizing the binding of NO to the enzyme's heme group, thereby amplifying the signal from any available NO.[2]
2. NO-Independent Direct Stimulation: Crucially, Riociguat also directly stimulates sGC at an allosteric binding site, distinct from the NO binding site. This action is independent of NO levels, allowing it to bypass the primary pathological defect of NO deficiency.[2]

• Net Therapeutic Effect: By restoring pathway activity through these two complementary mechanisms, Riociguat leads to a substantial increase in intracellular cGMP levels. This results in potent and sustained vasodilation of the pulmonary arteries, which reduces the afterload on the right ventricle, lowers pulmonary artery pressure, and ultimately improves blood flow and exercise capacity for the patient.[2]

4.2. Pharmacokinetics

The pharmacokinetic profile of Riociguat is characterized by good oral absorption, high protein binding, extensive metabolism through multiple pathways, and a half-life that supports three-times-daily dosing. Its disposition is highly susceptible to interactions with drugs that affect key metabolic enzymes and transporters.

Parameter	Value / Description	Clinical Implication / Note	Source(s)
Absorption	Oral administration. Food does not have a clinically relevant effect on exposure, but peak levels are higher in the fasted state.	For patients prone to hypotension, consistent intake with or without food is recommended to avoid fluctuations in peak concentration. Antacids reduce absorption and must be separated by ≥1 hour.	20
Distribution	High plasma protein binding (~95%), mainly to albumin and α1-acidic glycoprotein.	High binding can influence drug interactions, but the clinical significance is secondary to metabolic interactions.	5
	Volume of distribution at steady state (Vss​) is moderate, ~30 L.	Indicates distribution into tissues beyond the plasma volume.	5
Metabolism	Major pathway is N-demethylation to the major active metabolite, M1 (BAY 60-4552), which has 1/10 to 1/3 the activity of Riociguat. M1 is further metabolized to an inactive glucuronide.	The presence of an active metabolite contributes to the overall pharmacodynamic effect.	5
	Catalyzed by multiple Cytochrome P450 enzymes: CYP1A1, CYP3A4, CYP2C8, and CYP2J2.	The involvement of multiple CYPs, especially the highly inducible CYP1A1 and CYP3A4, is the primary reason for the extensive pharmacokinetic drug interaction profile.	5
Elimination	Low-clearance drug with a systemic clearance of ~3–6 L/h.	Low clearance makes the drug more susceptible to changes in concentration from inhibiting or inducing drugs.	5
Half-life (t1/2​)	~7 hours in healthy subjects. ~12–13 hours in patients with PH.	The longer half-life in patients contributes to achieving steady-state concentrations. The value supports a three-times-daily dosing interval.	5
Key Transporters	Substrate of efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).	Co-administration with potent inhibitors of these transporters can significantly increase Riociguat exposure, increasing the risk of hypotension.	5

The complex interplay of metabolic pathways is a critical determinant of Riociguat's clinical behavior. Its reliance on multiple CYP enzymes and key efflux transporters means that a clinician cannot prescribe the drug without a meticulous review of a patient's concomitant medications and lifestyle factors. For instance, strong inhibitors of both CYP enzymes and P-gp/BCRP transporters, such as azole antifungals (ketoconazole) and certain HIV protease inhibitors (ritonavir), can cause a profound increase in Riociguat exposure, necessitating a lower starting dose and careful monitoring for hypotension.[20] Conversely, strong inducers of these pathways, such as rifampin or St. John's Wort, can dramatically lower Riociguat levels, potentially leading to a loss of efficacy.[29] This pharmacokinetic vulnerability is a central challenge in the clinical application of Riociguat.

Clinical Application and Efficacy

The clinical use of Riociguat is targeted at specific, well-defined patient populations with pulmonary hypertension. Its efficacy has been robustly demonstrated in pivotal clinical trials, leading to its approval and integration into treatment guidelines.

5.1. Approved Indications

Riociguat is indicated for the treatment of adult patients in two distinct WHO Groups of pulmonary hypertension:

• Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4): Riociguat is approved for patients with persistent or recurrent CTEPH after surgical treatment (pulmonary endarterectomy), or for patients with inoperable CTEPH, with the goal of improving exercise capacity and WHO Functional Class.[2] The approval for this indication was a landmark achievement, as Riociguat was the first medication to be approved for this condition, which previously had no licensed pharmacotherapeutic options.[2] Efficacy has been established primarily in patients with WHO Functional Class II to III.[7]
• Pulmonary Arterial Hypertension (PAH, WHO Group 1): Riociguat is approved to improve exercise capacity, improve WHO Functional Class, and delay clinical worsening.[6] Its efficacy has been demonstrated when used as monotherapy or in combination with endothelin receptor antagonists (ERAs) or prostanoids.[6] The approval covers several etiologies within WHO Group 1, including idiopathic PAH (IPAH), heritable PAH (HPAH), and PAH associated with connective tissue disease.[31]

5.2. Dosing and Administration

The administration of Riociguat requires a careful, individualized dose-titration process to balance efficacy with the risk of hypotension. Treatment must be initiated and supervised by a physician with expertise in the management of PH.[20]

Phase	Duration	Dose	Monitoring Requirement / Condition	Source(s)
Starting Dose (Standard)	2 weeks	1 mg, 3 times daily	Initiate therapy.	3
Starting Dose (Hypotension Risk)	2 weeks	0.5 mg, 3 times daily	Use for patients with SBP <95 mmHg, those prone to hypotension, or those on strong CYP/P-gp inhibitors.	2
Titration Step	Every 2 weeks	Increase by 0.5 mg, 3 times daily	Only increase if systolic blood pressure (SBP) is ≥95 mmHg and the patient has no signs or symptoms of hypotension.	2
Maintenance	Ongoing	The established individual dose	Maintain the highest tolerated dose.	25
Maximum Dose (Standard)	Ongoing	2.5 mg, 3 times daily	This is the maximum recommended dose for most patients.	3
Maximum Dose (Smokers)	Ongoing	>2.5 mg, 3 times daily	Higher doses may be considered, if tolerated, due to reduced drug exposure. Safety and efficacy not formally established.	29
Dose Reduction	As needed	Decrease by 0.5 mg, 3 times daily	If at any time SBP falls below 95 mmHg and the patient shows signs of hypotension (e.g., dizziness).	2

Administration Notes:

• Doses should be taken approximately 6 to 8 hours apart.[25]
• For patients who cannot swallow tablets, they may be crushed and mixed with water or soft food like apple sauce immediately prior to oral administration.[20]

5.3. Summary of Clinical Evidence

The efficacy of Riociguat is supported by data from two pivotal, randomized, double-blind, placebo-controlled Phase 3 trials:

• CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1): This trial evaluated Riociguat in patients with inoperable CTEPH or persistent/recurrent CTEPH post-surgery.[2]
• Primary Endpoint: After 16 weeks of treatment, patients in the Riociguat group demonstrated a statistically significant and clinically meaningful improvement in 6MWD, walking an average of 46 meters further than patients receiving placebo.[8]
• Secondary Endpoints: Riociguat also led to significant improvements in secondary endpoints, including a reduction in pulmonary vascular resistance (PVR) and levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stress.[7]
• Long-Term Data: The open-label extension study, CHEST-2, showed sustained benefit, with a survival probability of over 90% at 2 years, though these uncontrolled data must be interpreted with caution.[7]
• PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1): This trial assessed Riociguat in patients with PAH.[2]
• Primary Endpoint: After 12 weeks, patients treated with Riociguat had a mean improvement in 6MWD that was 36 meters greater than that of the placebo group.[8]
• Secondary Endpoints: Significant improvements were also observed in PVR, NT-proBNP levels, WHO Functional Class, and time to clinical worsening.[2]
• Evidence for Switching Therapy (RESPITE and REPLACE Trials): A critical area of clinical investigation has been the strategy of switching patients from a PDE-5 inhibitor (e.g., sildenafil, tadalafil) to Riociguat. This addresses a common clinical scenario where patients on first-line PDE-5i therapy fail to achieve their treatment goals.[28] The rationale is that in advanced disease, NO bioavailability may be so depleted that PDE-5 inhibitors lose efficacy, whereas Riociguat's NO-independent mechanism remains effective.[28]
• The REPLACE trial, a prospective, randomized study, directly compared switching to Riociguat versus continuing PDE-5i therapy in PAH patients at intermediate risk.[35] The study found that switching to Riociguat led to a significantly higher rate of clinical improvement and a markedly lower rate of clinical worsening compared to maintaining PDE-5i treatment.[36] These findings provide strong, evidence-based support for positioning Riociguat not only as an initial therapy but also as a strategic sequential option for a well-defined patient population experiencing an inadequate response to standard care. This elevates its role from being just one of several choices to being a specific solution for a documented therapeutic failure.

Safety Profile and Risk Management

The clinical use of Riociguat is governed by a significant and multifaceted safety profile. The potential for serious adverse events necessitates a comprehensive risk management strategy, expert physician oversight, and thorough patient education.

6.1. Boxed Warning: Embryo-Fetal Toxicity

Riociguat carries a U.S. Boxed Warning, the most stringent warning issued by the FDA, regarding its potential to cause fetal harm.

WARNING: EMBRYO-FETAL TOXICITY

• Do not administer Adempas to a pregnant female because it may cause fetal harm.[4]
• Teratogenic Risk: Animal reproduction studies have consistently demonstrated that Riociguat is teratogenic. Oral administration to pregnant rabbits during organogenesis resulted in a range of adverse outcomes, including abortions, fetal toxicity, and structural abnormalities.[4]
• Clinical Mandate: Due to this risk, Riociguat is classified as Pregnancy Category X and is absolutely contraindicated for use in pregnant women.[10] If a patient becomes pregnant during therapy, she must be immediately informed of the potential hazard to the fetus.[4]

6.2. Adempas Risk Evaluation and Mitigation Strategy (REMS) Program

To manage the profound risk of embryo-fetal toxicity, Riociguat is available in the United States only through a restricted distribution program known as the Adempas REMS.[10]

• Program Goal: The sole purpose of the Adempas REMS is to prevent fetal exposure to the drug.[11]
• Key Stakeholder Requirements:
• Prescribers: Must be certified by enrolling in the program and completing specific training on the risks and requirements of Riociguat therapy.[10]
• Pharmacies: Must be certified with the REMS program and are only permitted to dispense Riociguat to patients who are authorized to receive it under the program's guidelines.[10]
• Female Patients: All female patients must be enrolled in the Adempas REMS program prior to initiating therapy.[10] This requirement is notably broad and includes prepubertal females and females who are not of reproductive potential (e.g., post-menopausal or surgically sterilized).[32] This universal enrollment for all females, regardless of their individual pregnancy risk, reflects a maximally cautious approach by regulators and the manufacturer. It simplifies the program's logistics by applying a single rule, thereby creating a robust system designed to eliminate any possibility of a patient's reproductive status being misclassified or changing without being captured. This administrative burden is considered an acceptable trade-off for achieving a zero-exposure goal.
• Females of Reproductive Potential (FRP): In addition to enrollment, FRP must comply with stringent pregnancy testing and contraception requirements. This includes obtaining a negative pregnancy test before starting treatment, monthly during treatment, and for one month after the final dose.[3] They must also use one or more forms of effective contraception during treatment and for one month after discontinuation.[10]
• Male Patients: Male patients are not required to enroll in the Adempas REMS program.[10]

6.3. Contraindications

In addition to pregnancy, Riociguat is strictly contraindicated in several other clinical situations due to the risk of severe adverse events:

• Concomitant use of Nitrates or Nitric Oxide (NO) Donors: Co-administration with any form of nitrate (e.g., nitroglycerin, isosorbide dinitrate/mononitrate) or NO donors (e.g., amyl nitrite, often used recreationally as "poppers") is contraindicated due to the high risk of profound and potentially life-threatening hypotension.[10]
• Concomitant use of Phosphodiesterase (PDE) Inhibitors: Co-administration with both specific PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) and non-specific PDE inhibitors (e.g., dipyridamole, theophylline) is contraindicated, also due to the risk of severe hypotension.[10] Strict washout periods are required when transitioning between these agents and Riociguat.[10]
• Concomitant use of other sGC Stimulators: Use with other drugs in the same class, such as vericiguat, is contraindicated.[10]
• Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias (PH-IIP): Riociguat is contraindicated in this patient population. A clinical trial in patients with PH-IIP was terminated prematurely due to an observed increase in mortality and serious adverse events compared to placebo.[3]
• Severe Hepatic Impairment (Child-Pugh C): Use is contraindicated in these patients as they have not been studied.[20]

6.4. Warnings and Precautions

• Hypotension: As a potent vasodilator, Riociguat can cause symptomatic hypotension. Caution is warranted in patients with pre-existing low blood pressure, hypovolemia (low blood volume), severe left ventricular outflow obstruction, or autonomic dysfunction. Patients over 65 years of age are at an increased risk.[20]
• Bleeding: There is an increased risk of serious bleeding. In pooled clinical trial data, serious bleeding events occurred in 2.4% of patients taking Adempas versus 0% of placebo patients.[42] These events included hemoptysis (coughing up blood), which was fatal in one case, as well as vaginal hemorrhage, subdural hematoma, and gastrointestinal hemorrhage.[37] The use of Riociguat should be avoided in patients with a history of serious hemoptysis.[31]
• Pulmonary Veno-Occlusive Disease (PVOD): Pulmonary vasodilators, including Riociguat, can significantly worsen the cardiovascular status of patients with PVOD, a rare form of PH. If a patient develops signs of pulmonary edema (fluid in the lungs) while on therapy, the possibility of associated PVOD should be considered, and treatment should be discontinued if it is confirmed.[31]

6.5. Adverse Reactions

The adverse reaction profile of Riociguat is primarily driven by its vasodilatory effects on vascular and gastrointestinal smooth muscle.

System Organ Class	Adverse Reaction	Riociguat Frequency (%)	Placebo Frequency (%)	Source(s)
Nervous system	Headache	27	18	10
	Dizziness	20	13	10
Gastrointestinal	Dyspepsia / Gastritis	21	8	10
	Nausea	14	11	10
	Diarrhea	12	8	10
	Vomiting	10	7	10
	Gastroesophageal reflux disease (GERD)	5	2	10
	Constipation	≥3	<3	4
Vascular	Hypotension	10	4	10
Hematologic	Anemia	7	2	10
	Bleeding (serious)	2.4	0	42
General	Peripheral edema	≥3	<3	39
Respiratory	Epistaxis (nosebleeds)	≥3	<3	3

Other potentially related adverse events seen more frequently with Riociguat include palpitations, nasal congestion, and dysphagia (difficulty swallowing).[7]

Drug Interactions

The clinical management of Riociguat is heavily influenced by its extensive potential for drug-drug interactions. These interactions can be pharmacodynamic, resulting from additive effects on blood pressure, or pharmacokinetic, stemming from alterations in the drug's metabolism and transport.

Pharmacodynamic Interactions

These interactions primarily involve an additive risk of hypotension due to synergistic effects on vasodilation.

• Contraindicated Combinations: The most critical interactions are pharmacodynamic. Co-administration of Riociguat with the following agents is contraindicated due to the risk of severe, unpredictable, and potentially life-threatening hypotension [10]:
• Nitrates and Nitric Oxide Donors: Any form of organic nitrate (e.g., nitroglycerin, isosorbide dinitrate) or NO donor (e.g., amyl nitrite).
• Phosphodiesterase (PDE) Inhibitors: This includes both PDE-5 inhibitors used for PAH or erectile dysfunction (sildenafil, tadalafil, vardenafil) and non-specific PDE inhibitors (theophylline, dipyridamole).
• Interactions Requiring Caution: The hypotensive effects of Riociguat can be potentiated by other drugs that lower blood pressure. Concomitant use with antihypertensives, beta-blockers, calcium channel blockers, and diuretics requires careful blood pressure monitoring, particularly during dose titration.[6]

Pharmacokinetic Interactions

These interactions arise from the influence of other drugs on the enzymes (CYP450) and transporters (P-gp, BCRP) responsible for Riociguat's metabolism and elimination.

Interacting Agent/Class	Mechanism of Interaction	Clinical Effect on Riociguat	Management Recommendation	Source(s)
Strong Combined CYP and P-gp/BCRP Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir)	Inhibition of multiple metabolic and efflux pathways (CYP3A4, P-gp, BCRP).	Pronounced increase in Riociguat exposure.	Consider a reduced starting dose of 0.5 mg TID. Monitor closely for hypotension. Dose reduction may be required for patients who cannot tolerate the hypotensive effect.	20
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine, St. John's Wort)	Induction of CYP3A4-mediated metabolism.	Significant reduction (50-60%) in Riociguat exposure.	May lead to reduced efficacy. Higher doses (>2.5 mg TID) may be considered if tolerated, but data are limited. Avoid if possible.	29
Antacids (Aluminum hydroxide / Magnesium hydroxide)	Increased gastric pH reduces Riociguat solubility and absorption.	Decreased oral bioavailability and reduced efficacy.	Separate administration by at least 1 hour. Do not take antacid within 1 hour of a Riociguat dose.	4

Lifestyle Interactions

• Smoking: This interaction is of unique clinical importance. Tobacco smoke contains polycyclic aromatic hydrocarbons which are potent inducers of the CYP1A1 enzyme, a key pathway in Riociguat metabolism.[5]
• Effect: This induction leads to a 50-60% reduction in Riociguat plasma concentrations in smokers compared to non-smokers, an effect substantial enough to potentially negate the drug's therapeutic benefit at standard doses.[20]
• Clinical Management: This is not a static interaction but a dynamic variable. Patients who smoke may require titration to higher doses (potentially exceeding the standard 2.5 mg TID maximum) to achieve therapeutic exposure.[29] Conversely, and critically, patients who stop smoking while on an established dose of Riociguat are at risk for a sudden doubling of their drug exposure, which can precipitate severe hypotension. Therefore, patients must be counseled to stop smoking, and clinicians must be prepared to proactively reduce the dose if a patient quits. This requires ongoing dialogue about smoking status at every follow-up visit.

Use in Special Populations

The use of Riociguat requires specific considerations and dose adjustments in several special populations due to altered pharmacokinetics or heightened safety risks.

Pediatric Population

The regulatory status and recommendations for pediatric use differ between the U.S. and Europe.

• Regulatory Status:
• EMA: Adempas is indicated for the treatment of PAH in pediatric patients aged less than 18 years with a body weight of ≥50 kg, who are in WHO FC II or III, specifically in combination with an endothelin receptor antagonist (ERA).[26]
• FDA: In the U.S., the safety and effectiveness of Riociguat in pediatric patients have not been established.[46]
• Dosing (EMA Guidelines): For approved pediatric use, a specific titration schedule is recommended, guided by age-dependent systolic blood pressure (SBP) thresholds. The dose is increased by 0.5 mg every two weeks up to a maximum of 2.5 mg three times daily, provided SBP remains ≥90 mmHg for children aged 6 to <12 years, or ≥95 mmHg for adolescents aged 12 to <18 years, without signs of hypotension.[20]
• Populations to Avoid: Use is not recommended or established in:
• Children under 6 years of age, due to non-clinical findings of adverse effects on growing bone.[20]
• Children and adolescents with CTEPH.[20]
• Children initiating therapy with SBP below the specified age-based thresholds.[20]

Geriatric Population (≥65 years)

While clinical trials did not identify geriatric-specific problems that would preclude its use, elderly patients may be more sensitive to the drug's effects.[3] They are at an increased risk of hypotension, and pharmacokinetic data show that plasma concentrations are approximately 40% higher in this group, primarily due to reduced renal and non-renal clearance. Therefore, particular caution should be exercised during the individual dose titration phase.[20]

Renal Impairment

• Mild to Moderate Impairment (Creatinine Clearance [CrCl] 30-80 mL/min): Patients in this group have shown higher exposure to Riociguat. This increases the risk of hypotension, and prescribers should exercise particular care during dose titration.[20]
• Severe Impairment (CrCl < 30 mL/min) and Patients on Dialysis: Data in these populations are limited or non-existent. Due to the potential for significantly increased drug exposure and unknown safety, the use of Riociguat is not recommended.[20]

Hepatic Impairment

• Mild Impairment (Child-Pugh A): No dose adjustment is required, but patients should be monitored carefully.
• Moderate Impairment (Child-Pugh B): Patients in this group have shown markedly increased exposure to Riociguat. Particular care must be exercised during individual dose titration.[20]
• Severe Impairment (Child-Pugh C): Patients with severe hepatic impairment have not been studied. The use of Riociguat in this population is contraindicated.[20]

Population	Level of Impairment / Condition	Recommendation	Rationale / Note	Source(s)
Pediatric	PAH, <18 years, ≥50 kg (EMA)	Use in combo with ERA; specific titration based on age/SBP.	Efficacy established in this specific subgroup.	20
	<6 years of age	Not recommended.	Safety concern regarding adverse effects on growing bone.	20
Geriatric	≥65 years	Use with caution during titration.	Increased risk of hypotension and ~40% higher drug exposure.	20
Renal Impairment	Severe (CrCl < 30 mL/min) or on Dialysis	Not recommended.	Limited/no data; risk of significantly increased exposure.	20
	Mild to Moderate (CrCl 30-80 mL/min)	Use with caution during titration.	Increased drug exposure and higher risk of hypotension.	20
Hepatic Impairment	Severe (Child-Pugh C)	Contraindicated.	Not studied; risk is unknown and potentially high.	20
	Moderate (Child-Pugh B)	Use with caution during titration.	Markedly increased drug exposure.	20
Smokers	Current Smokers	Advise to quit. Dose increase may be needed.	50-60% reduction in plasma concentration due to CYP1A1 induction.	20
	Patients who Quit Smoking	Dose reduction should be considered.	Risk of sudden doubling of drug exposure, leading to hypotension.	20

Conclusion and Clinical Perspective

Riociguat (Adempas®) represents a significant and innovative contribution to the pharmacotherapy of pulmonary hypertension. As the first-in-class soluble guanylate cyclase stimulator, its novel dual mechanism of action—directly stimulating sGC and sensitizing it to endogenous nitric oxide—offers a distinct therapeutic advantage, particularly in the context of the NO-deficient state that characterizes advanced PH.

The clinical value of Riociguat is most profound in two key areas. First, it stands as the only approved medical therapy for patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), filling a critical therapeutic void for a patient population with limited options. Second, in the more crowded field of pulmonary arterial hypertension (PAH), it has established itself not only as an effective initial therapy but also as a vital evidence-based "switch" option for patients who have an inadequate response to first-line PDE-5 inhibitors. This provides a crucial next step in the treatment algorithm before escalating to more complex therapies.

However, the substantial benefits of Riociguat are inextricably linked to a formidable safety and risk management profile. The absolute contraindication in pregnancy, managed through a stringent and mandatory REMS program, places a significant logistical and educational burden on the entire healthcare ecosystem—prescribers, pharmacists, and patients alike. The absolute contraindication with nitrates and PDE-5 inhibitors, coupled with a wide array of other clinically significant drug-drug and lifestyle (smoking) interactions, demands a level of physician expertise and patient vigilance that is greater than that for many other cardiovascular agents.

Ultimately, the decision to initiate Riociguat therapy is a complex exercise in risk-benefit analysis. The potential for marked improvements in exercise capacity, functional status, and hemodynamics in patients suffering from debilitating and life-threatening diseases must be carefully weighed against the absolute risk of teratogenicity, the potential for severe hypotension and bleeding, and the complexities of its administration. Safe and effective use of Riociguat is therefore critically dependent on meticulous patient selection, comprehensive education, and diligent, ongoing monitoring by a physician experienced in its use. It is a landmark drug that has changed the treatment landscape for PH, but one that commands respect for its power and its potential for harm.

Works cited

1. Riociguat | C20H19FN8O2 | CID 11304743 - PubChem, accessed July 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Riociguat
2. Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension, accessed July 28, 2025, https://www.ahdbonline.com/issues/2014/march-2014-volume-7-special-feature-fifth-annual-payers-guide-to-new-fda-approvals/adempas-riociguat-a-novel-first-in-class-therapy-approved-for-the-treatment-of-2-types-of-pulmonary-hypertension
3. Riociguat (oral route) - Side effects & dosage - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/riociguat-oral-route/description/drg-20061342
4. ADEMPAS (riociguat) tablets - accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204819s006lbl.pdf
5. Riociguat - Therapeutic Goods Administration (TGA), accessed July 28, 2025, https://www.tga.gov.au/sites/default/files/auspar-riociguat-140612-pi.docx
6. Riociguat: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB08931
7. cteph efficacy + safety results - Adempas (riociguat), accessed July 28, 2025, https://www.adempashcp.com/cteph-efficacy
8. Adempas - riociguat, accessed July 28, 2025, https://www.1111hk.com/wp-content/uploads/2019/01/%E5%88%A9%E5%A5%A5%E8%A5%BF%E5%91%B1%E7%89%87%E8%8B%B1%E6%96%87%E4%BA%A7%E5%93%81%E8%AF%B4%E6%98%8E.pdf
9. Riociguat: first global approval - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/24218053/
10. Adempas (riociguat) | Official Site, accessed July 28, 2025, https://www.adempashcp.com/
11. Prior Authorization Protocol ADEMPAS® (riociguat) NATL - Health Net, accessed July 28, 2025, https://www.healthnet.com/static/general/unprotected/html/national/pa_guidelines/ADEMPAS_NATL.pdf
12. Adempas (riociguat) dosing, indications, interactions, adverse effects, and more, accessed July 28, 2025, https://reference.medscape.com/drug/adempas-riociguat-999863
13. Adempas (riociguat) FDA Approval History - Drugs.com, accessed July 28, 2025, https://www.drugs.com/history/adempas.html
14. Drug ID - ADReCS, accessed July 28, 2025, https://www.bio-add.org/ADReCS/drugSummary.jsp?drug_id=BADD_D01948&uname=b1e8dff1-1c95-49ee-b758-6af794ddd4c5
15. Riociguat | C20H19FN8O2 - ChemSpider, accessed July 28, 2025, https://www.chemspider.com/Chemical-Structure.9479719.html
16. Riociguat (BAY 63-2521, CAS Number: 625115-55-1) | Cayman Chemical, accessed July 28, 2025, https://www.caymanchem.com/product/9000554/riociguat
17. Riociguat - brand name list from Drugs.com, accessed July 28, 2025, https://www.drugs.com/ingredient/riociguat.html
18. Riociguat | CAS 625115-55-1 | SCBT - Santa Cruz Biotechnology, accessed July 28, 2025, https://www.scbt.com/p/riociguat-625115-55-1
19. Riociguat - Chemical Details, accessed July 28, 2025, https://comptox.epa.gov/dashboard/chemical/details/DTXSID50978109
20. Adempas, INN- riociguat - EMA, accessed July 28, 2025, https://www.ema.europa.eu/en/documents/product-information/adempas-epar-product-information_en.pdf
21. www.accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=406913
22. www.phaeurope.org, accessed July 28, 2025, https://www.phaeurope.org/news/drug-information/#:~:text=Riociguat%20(Adempas)%2C%20a%20new,)%20on%20March%2027%2C%202014.%2520on%2520March%252027%252C%25202014.&sa=D&source=editors&ust=1753698076680015&usg=AOvVaw0WzIddQxnLysJkebWV6bKT)
23. When will the ADEMPAS patents expire, and when will generic ADEMPAS be available? - DrugPatentWatch, accessed July 28, 2025, https://www.drugpatentwatch.com/p/tradename/ADEMPAS
24. Drug Information - PHA Europe, accessed July 28, 2025, https://www.phaeurope.org/news/drug-information/
25. TRANSPARENCY COMMITTEE - Haute Autorité de Santé, accessed July 28, 2025, https://www.has-sante.fr/jcms/c_2022142/fr/adempas-ct13594-version-anglaise
26. Adempas | European Medicines Agency (EMA), accessed July 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/adempas
27. Generic Adempas Availability - Drugs.com, accessed July 28, 2025, https://www.drugs.com/availability/generic-adempas.html
28. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors - ERS Publications, accessed July 28, 2025, https://publications.ersnet.org/content/erj/50/3/1602425
29. drug interactions 1 - Adempas (riociguat), accessed July 28, 2025, https://www.adempashcp.com/managing-adempas
30. Riociguat - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Riociguat
31. Prescribing Information - Adempas (riociguat), accessed July 28, 2025, https://www.adempas-us.com/prescribing-information
32. Riociguat Monograph for Professionals - Drugs.com, accessed July 28, 2025, https://www.drugs.com/monograph/riociguat.html
33. Practical management of riociguat in patients with pulmonary arterial hypertension - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6710674/
34. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9909097/
35. Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i, accessed July 28, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/riociguat-replacing-pde-5i-therapy-evaluated-against-continued-pde-5i/
36. Switching from PDE-5is to riociguat may be a new treatment strategy for PAH - MIMS, accessed July 28, 2025, https://www.mims.com/vietnam/news-updates/topic/switching-from-pde-5is-to-riociguat-may-be-a-new-treatment-strategy-for-pah
37. Riociguat: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed July 28, 2025, https://www.rxlist.com/riociguat/generic-drug.htm
38. Bayer's Adempas - Pharmacy Times, accessed July 28, 2025, https://www.pharmacytimes.com/view/bayers-adempas
39. Adempas (riociguat) | Official Site, accessed July 28, 2025, https://www.adempas-us.com/
40. Riociguat (oral route) - Side effects & dosage - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/riociguat-oral-route/side-effects/drg-20061342
41. Riociguat (Adempas) - Pulmonary Hypertension Association, accessed July 28, 2025, https://phassociation.org/patients/treatments/riociguat/
42. PAH CHD - Adempas (riociguat), accessed July 28, 2025, https://www.adempashcp.com/pah-chd
43. Riociguat Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 28, 2025, https://www.drugs.com/sfx/riociguat-side-effects.html
44. 8 Adempas (Riociguat) Interactions: Paxlovid, Smoking, Viagra, and More - GoodRx, accessed July 28, 2025, https://www.goodrx.com/adempas/interactions
45. ADEMPAS 2 mg cp pellic - VIDAL, accessed July 28, 2025, https://www.vidal.fr/medicaments/adempas-2-mg-cp-pellic-141397.html
46. Riociguat Tablets - [Product Monograph Template - Standard], accessed July 28, 2025, https://pdf.hres.ca/dpd_pm/00077588.PDF